Objectives Laboratory assessment of disease activity is one of the main difficulties in patients with Takayasu's arteritis (TAK), during follow-up. To date, no biomarker is validated for clinical activity in TAK. In this study, we aimed to investigate serum GM-CSF, IL-6, IL-8, IL-10, IL-18 and IL-23 levels and their correlations with disease activity in patients with TAK.
Methods The study included 74 patients (age: 41.8±13.5 years, F/M: 64/10) with TAK fulfilling ACR criteria and 42 age and sex-matched healthy controls (age: 38.1±7.4 years, F/M: 38/4). TAK patients were evaluated by physician's global assessment (PGA; active/inactive) and by Kerr et al. definition (if available in the current visit) in terms of clinical activity. Fifty-one of 74 patients had a follow-up visit. Commercial ELISA kits were used for the measurement of serum GM-CSF, IL-6, IL-8, IL-10, IL-18 and IL-23. ESR and CRP levels were also measured.
Results At baseline, 37 (50%) patients were active according to PGA. Kerr' activity criteria were available for 62 patients and 24.2% (n=15) of these were active. Serum IL-8 and IL-18 levels were significantly higher in patients with TAK, whereas GM-CSF, IL-6, IL-10, IL-23 levels were similar to healthy controls. There was no difference between active and inactive patients regarding any cytokine level. ESR significantly correlated with IL-23 and CRP with IL-18 levels. Serum IL-6, IL-8 and IL-10 levels were significantly higher in patients taking corticosteroid therapies. In the follow-up visit, clinical activity rate decreased to 19.6% from 50% according to PGA. IL-8 levels significantly decreased and IL-23 levels significantly increased in follow-up compared to baseline.
Conclusions We found significantly increased IL-8 and IL-18 level in patients with TAK and IL-18 levels correlated with CRP. IL-8 levels significantly decreased in the follow-up together with a decrease in the rate of clinical activity. These findings suggest that IL-8 and IL-18 might be important mediators for TAK pathogenesis and their blockage might be new therapeutic approaches.
Disclosure of Interest None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.